|
Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate
|
DB04523 |
|
|
Malonyl-CoA
|
DB04524 |
[A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.] |
|
CLX-0921
|
DB05854 |
[CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.] |
|
GSHNA
|
DB04521 |
|
|
Dexfosfoserine
|
DB04522 |
[The phosphoric acid ester of serine.] |
|
cryopreserved human liver cells
|
DB05852 |
[Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. ] |
|
Biomed 101
|
DB05851 |
[Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
] |
|
(3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione
|
DB04520 |
|
|
Parathyroid hormone
|
DB05829 |
[Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).
Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).] |
|
LU-31130
|
DB05828 |
[LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.
It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.
] |
|
G207
|
DB05827 |
[G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known as the cause of cold sores. MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.] |
|
Prolease-r-hFSH
|
DB05826 |
[Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.] |
|
NCX 1015
|
DB05825 |
[NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.] |
|
CNS-5161
|
DB05824 |
[CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
] |
|
DP-VPA
|
DB05821 |
[DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.] |
|
DP-b99
|
DB05820 |
[DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.] |
|
N-Methylnaloxonium
|
DB04509 |
|
|
BG-777
|
DB05839 |
[BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.] |
|
Methyl(6s)-1-Thio-L-Manno-Hexodialdo-6,2-Pyranoside
|
DB04508 |
|
|
OPC-51803
|
DB05838 |
[OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.] |
